From: Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E
T3 form | Breast cancer cells | IC50 [μM] (time of treatments) | References |
---|---|---|---|
δ-T3 | MDA-MB-231a | 22.6h (48 h) | (Guthrie et al. 1997) |
MCF7b | 5.5h (48 h) | ||
CL-S1d | 7h (5 days) | (McIntyre et al. 2000) | |
−SAe | 4h (5 days) | ||
+SAf | 3h (5 days) | ||
MDA-MB-231 | 10h (48 h) | (Elangovan et al. 2008) | |
MDA-MB-231 | 20h (72 h) | ||
SKBr3g | 45.6h (24 h) | (Pierpaoli et al. 2010) | |
SKBr3g | 31.5h (48 h) | ||
γ-T3 | MDA-MB-231a | 73h (48 h) | (Guthrie et al. 1997) |
MCF7b | 4.87h (48 h) | ||
CL-S1d | 8h (5 days) | (McIntyre et al. 2000) | |
−SAe | 5h (5 days) | ||
+SAf | 4h (5 days) | ||
SKBr3g | 55.2h (24 h) | (Pierpaoli et al. 2010) | |
SKBr3g | 34h (48 h) | ||
α-T3 | MDA-MB-231a | >100h (24 h) | (Guthrie et al. 1997) |
MCF7b | 14.2a (48 h) | ||
TRF | 4T1c | 8 ug/mlh (72 h) | (Hafid et al. 2009) |